Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15:141.

Article  Google Scholar 

Ishikawa Y, Miura T, Aoyagi T, Ogata H, Hamada S, Minami R. Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromuscul Disord. 2011;21:47–51.

Article  Google Scholar 

Matsumura T, Saito T, Fujimura H, Shinno S, Sakoda S. A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy. Rinsho Shinkeigaku. 2011;51:743–50.

Article  Google Scholar 

Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S, GFR CDtJEfE. GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis. 2013;61:197–203.

Article  CAS  Google Scholar 

Viollet L, Gailey S, Thornton DJ, Friedman NR, Flanigan KM, Mahan JD, et al. Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve. 2009;40:438–42.

Article  CAS  Google Scholar 

Kimura K, Morita H, Daimon M, Horio M, Kawata T, Nakao T, et al. Utility of cystatin C for estimating glomerular fltration rate in patients with muscular dystrophy. Int Heart J. 2016;57:386–8.

Article  CAS  Google Scholar 

Braat E, Hoste L, De Waele L, Gheysens O, Vermeersch P, Goffin K, et al. Renal function in children and adolescents with Duchenne muscular dystrophy. Neuromuscul Disord. 2015;25:381–7.

Article  Google Scholar 

Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28:830–8.

Article  CAS  Google Scholar 

Cimerman N, Brguljan PM, Krasovec M, Suskovic S, Kos J. Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta. 2000;300:83–95.

Article  CAS  Google Scholar 

Matsumura T, Saito T, Fujimura H, Sakoda S. Renal dysfunction is a frequent complication in patients with advanced stage of Duchenne muscular dystrophy. Rinsho Shinkeigaku. 2012;52:211–7.

Article  Google Scholar 

Motoki T, Shimizu-Motohashi Y, Komaki H, Mori-Yoshimura M, Oya Y, Takeshita E, et al. Treatable renal failure found in non-ambulatory Duchenne muscular dystrophy patients. Neuromuscul Disord. 2015;25:754–7.

Article  Google Scholar 

Villa CR, Kaddourah A, Mathew J, Ryan TD, Wong BL, Goldstein SL, et al. Identifying evidence of cardio-renal syndrome in patients with Duchenne muscular dystrophy using cystatin C. Neuromuscul Disord. 2016;26:637–42.

Article  Google Scholar 

Motoki T, Shimizu-Motohashi Y, Saito I, Komaki H, Ishiyama A, Aibara K, et al. Renal dysfunction can occur in advanced-stage Duchenne muscular dystrophy. Muscle Nerve. 2020;61:192–7.

Article  CAS  Google Scholar 

Kagen LJ, Moussavi S, Miller SL, Tsairis P. Serum myoglobin in muscular dystrophy. Muscle Nerve. 1980;3:221–6.

Article  CAS  Google Scholar 

Adachi Y, Tamura R, Shindo T, Sasaki K, Masaki T, Nozu K, et al. A case of hereditary FSGS with Duchenne muscular dystrophy diagnosed in childhood. Jpn J Nephrol. 2021;63:831 (In Japanese).

Google Scholar 

Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17:347–61.

Article  Google Scholar 

Quinlivan R, Messer B, Murphy P, Astin R, Mukherjee R, Khan J, et al. Adult North Star Network (ANSN): consensus guideline for the standard of care of adults with Duchenne muscular dystrophy. J Neuromuscul Dis. 2021;8:899–926.

Article  CAS  Google Scholar 

Suehara M, Nagata A, Saito M, Kanzato N. 2cases of trying positive treatment to further complication after appearance of cardiopulmonary function failure In: Ministry of health and welfare editor. Reports of the clinical research team for the genetic counselling and the clinical research of the pathophysiology and treatment in muscular dystrophy patients. Kodaira: National Center of Neurology and Psychiatry; 1999. p. 430 (In Japanese)